期刊
IMMUNITY
卷 40, 期 5, 页码 657-668出版社
CELL PRESS
DOI: 10.1016/j.immuni.2014.04.009
关键词
-
类别
资金
- IAVI through the NAC
- NIH [AI33232, AI098484, AI095098]
- CHAVI-ID [UM1AI100663]
- Ragon Institute
- AIDS fonds Netherlands [2011032, 2012041]
- HIVRAD [P01 AI82362]
- DAAD
- CA HIV/AIDS Research Program
- Vidi grant NWO [ERC-StG-2011-280829-SHEV]
- NSC [101-CDA-L07, 101-2321-B-001-024, 102-2321-B-001-017]
- CFG glycan microarrays [GM62116, GM098791]
- Bill & Melinda Gates Foundation
- United States Agency for International Development (USAID)
- [AI69993]
- [AI98602]
- [T32 AI007244]
- [GRS/79268]
- [EP/G037604/1]
- [WT093378MA]
- [WT099197MA]
- [U01 CA128416]
- EPSRC [EP/G037604/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [GR/S79268/02, EP/G037604/1] Funding Source: researchfish
Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccine design, both as templates and as indicators of the authenticity of vaccine candidates, (b) to assist in structural studies, and (c) to serve as potential therapeutics. However, the number of targets on the viral envelope spike for such antibodies has been limited. Here, we describe a set of human monoclonal antibodies that define what is, to the best of our knowledge, a previously undefined target on HIV Env. The antibodies recognize a glycan-dependent epitope on the prefusion conformation of gp41 and unambiguously distinguish cleaved from uncleaved Env trimers, an important property given increasing evidence that cleavage is required for vaccine candidates that seek to mimic the functional HIV envelope spike. The availability of this set of antibodies expands the number of vaccine targets on HIV and provides reagents to characterize the native envelope spike.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据